Used primarily in cancer research, AZD-7762 is a potent inhibitor of checkpoint kinases Chk1 and Chk2. It enhances the effectiveness of DNA-damaging agents such as chemotherapy and radiation by preventing cancer cells from repairing DNA damage, leading to increased cell death. It has shown promise in preclinical studies, particularly in tumors with p53 deficiencies, where Chk1 inhibition pushes cells toward apoptosis. AZD-7762 is investigated for use in combination therapies to overcome resistance to standard oncology treatments. Despite strong preclinical activity, clinical development has been limited due to toxicity concerns, but it remains a valuable tool compound for studying DNA damage response pathways.